EPIRUS’ BOW-015 achieves bioequivalence to Remicade in a single dose comparator trial

NewsGuard 100/100 Score

EPIRUS Biopharmaceuticals, Inc. ("EPIRUS"), formerly known as fourteen22 Inc, announced that its lead asset, BOW-015, achieved bioequivalence to Remicade® in a single dose comparator trial.

In February 2012, the United Kingdom's MHRA (Medicines and Healthcare Regulatory Agency) approved a single center, double blind, randomized parallel group trial in 84 healthy male volunteers each of whom received a 5 mg/kg single infusion of BOW-015 or Remicade®.

At the conclusion of the trial, BOW-015 met both the primary objectives of bioequivalence in Cmax, AUC(0-t) and AUC(0-∞), as well as the secondary objectives of safety, tolerability and immunogenicity.

"The data from this Phase 1 study are encouraging and support the bioequivalence of BOW-015 with Remicade.  Biosimilars, when developed with the proper rigor, will offer patients around the world similarly effective biological therapies that should be less costly than those currently available.  I look forward to seeing data from the ongoing Phase 3 trial," commented Jonathan Kay , MD, Professor of Medicine, University of Massachusetts Medical School, and Director of Clinical Research, Division of Rheumatology, UMass Memorial Medical Center, Worcester, Massachusetts.

EPIRUS is currently conducting a registrational Phase 3 program for BOW-015 with initial data expected in late 2013.

EPIRUS was financed in early 2011 by 5AM Ventures, Montreux Equity Partners and TPG Biotech.  Following a restructuring in 2012, EPIRUS has expanded its focus to centrally develop a broad pipeline of biosimilar monoclonal antibodies, optimised for use within its SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.  This innovative platform is designed to enable localized manufacturing in key emerging economies where EPIRUS is developing partnerships combining public and private sector financial support and expertise.

EPIRUS President and Chief Executive Officer, Amit Munshi commented, "We are pleased with this initial data and are excited to continue working with our In Market partners globally to continue building out our product pipeline and regional manufacturing model."


EPIRUS Biopharmaceuticals, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Top minds in multiple sclerosis to speak at CMSC 38th Annual Meeting